<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01930006</url>
  </required_header>
  <id_info>
    <org_study_id>265-106</org_study_id>
    <nct_id>NCT01930006</nct_id>
  </id_info>
  <brief_title>Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State</brief_title>
  <official_title>Phase 1 Single Dose 2-Way Crossover Comparative Bioavailability Study Of Two Oral Formulations Of MGCD265 In Healthy Male And Female Subjects - Fasting State</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirati Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mirati Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study two MGCD265 oral formulations at dose level of 100 mg are administered to
      healthy male and female subjects under fasting conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to compare the rate and extent of absorption of two MGCD265
      oral formulations at a dose level of 100 mg administered to healthy male and female subjects
      under fasting conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the bioavailability of two MGCD265 formulations.</measure>
    <time_frame>Two months</time_frame>
    <description>To compare the rate and extent of absorption of two MGCD265 oral formulations at dose level of 100 mg administered as 1 x 100 mg oral dose (Formulation A) and 2 x 50 mg oral dose (Formulation B) under fasting conditions.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Advanced Malignancies</condition>
  <arm_group>
    <arm_group_label>MGCD265</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MGCD265</intervention_name>
    <arm_group_label>MGCD265</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male or female subjects ≥18 to ≤55 years of age who are willing and able to
             provide informed consent prior to performing any study related procedures

          2. Females of childbearing potential who are using a stable contraceptive method at least
             30 days prior to screening and who are willing to use one of the following acceptable
             birth control methods until 30 days after the last dose of study drug:

               1. Abstinence

               2. Hormonal contraceptives (birth control pills, injectable/ implantable/ insertable
                  hormonal birth control products, transdermal patch) for at least 3 months prior
                  to the first dose of the study drug and male condom and intravaginal spermicide

               3. Intra-uterine contraceptive device (IUD) in place for at least 3 months prior to
                  the first dose of study drug plus spermicide and male condom

               4. Male condom and diaphragm plus spermicide;

               5. Male condom and cervical cap plus spermicide;

               6. Surgical sterilization of the partner(s) (vasectomy for 6 months minimum prior to
                  the first dose of study drug)

          3. Female subjects will be considered of non childbearing potential and eligible if one
             of the following condition is met:

               1. Amenorrhea for at least 1 year, with confirmation by a follicle-stimulating
                  hormone (FSH ≥ 40 mIU/mL)

               2. Hysterectomy

               3. Bilateral oophorectomy

               4. Bilateral tubal ligation

          4. Male subjects must agree to be abstinent or use the following acceptable contraception
             methods in collaboration with their female partner from the time of taking the first
             dose until 3 months after the last dose of study drug:

               1. Male condom and intravaginal spermicide plus hormonal contraceptives (birth
                  control pills, injectable/ implantable/ insertable hormonal birth control
                  products, transdermal patch) in use for at least 3 months

               2. Male condom and IUD in place for at least 3 months plus spermicide;

               3. Male condom and diaphragm plus spermicide

               4. Male condom and cervical cap plus spermicide

               5. Vasectomy for 6 months minimum prior to the first dose of study drug

             Male subjects also agree to not donate sperm from the time of taking the first dose of
             study drug until 3 months after the last dose of study drug

          5. Subject with a body mass index (BMI) of 18.0 to 32.0 kg/m2 at screening

          6. Subject is a current non-smoker and has not used any nicotine containing product
             within 3 months prior to screening

          7. Subjects who are considered generally healthy upon completion of medical history,
             physical examination, vital signs, screening laboratory results and screening ECG as
             judged by the investigator

          8. Subjects who are willing and able to comply with the visit schedule, treatment plan,
             laboratory tests, pharmacokinetic sampling schedule and other study procedures

        Exclusion Criteria:

          1. Females who are pregnant or are breast feeding

          2. History of significant hypersensitivity reaction to any substance or drug

          3. Clinically relevant history or evidence of significant gastrointestinal, hepatic,
             renal, endocrine, pulmonary, neurological, psychiatric, cardiovascular, hematologic,
             dermatologic, immunologic disease or any other condition known to interfere with the
             absorption, distribution, metabolism or distribution of drugs that in the opinion of
             the investigator would jeopardize the safety of the subject or impact validity of
             study results

          4. Clinically significant vital signs in the opinion of the investigator at screening or
             prior to study drug administration

          5. History of clinically significant cardiovascular illness including but not confined
             to: angina pectoris or myocardial infarction, coronary or peripheral artery bypass
             graft, congestive heart failure, or clinically significant cardiac arrhythmia in the
             opinion of the investigator

          6. History of clinically significant thrombotic or hemorrhagic events (including but not
             confined to stroke and transient ischemic attacks); history of bleeding diathesis or
             coagulopathy; history or presence of gastrointestinal or other conditions with risk of
             perforation; presence of a non-healing wound, ulcer or fracture in the opinion of the
             investigator

          7. Presence of out-of-range cardiac interval (PR &lt; 110 msec, PR &gt; 200 msec, QRS &lt; 60
             msec, QRS &gt;110 msec and QTcF &gt; 450 msec) at screening or the pre-dose ECG or other
             clinically significant ECG abnormalities in the opinion of the investigator

          8. History of regular alcohol consumption exceed 7 drinks for females and 14 drinks per
             week for males within 6 months of screening or a positive alcohol breath test at
             screening and prior to study drug administration

          9. History of significant drug abuse within one year prior to screening

         10. Any clinically significant illness or surgery in the previous 30 days before day 1 of
             this study

         11. Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450
             (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin,
             fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP
             enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin, rifampin and
             St John's Wort), in the previous 30 days before day 1 of this study

         12. Use of any drugs known to induce or inhibit hepatic metabolism (inducers such as
             rifampin, barbiturates, carbamazepine, phenytoin, glucocorticoid, omeprazole;
             inhibitors such as antidepressants (SSRI), cimetidine, diltiazem, macrolides,
             imidazoles, neuroleptics, verapamil, fluroquinolones, antihistamines) in the previous
             30 days before day 1 of the study

         13. Use of any other prescription medications in the previous 14 days before day 1 of this
             study

         14. Use of any over-the-counter (OTC) products including cold preparations, multivitamins
             and dietary supplements used for therapeutic benefits and antacid preparations in the
             previous 7 days before day 1 of this study

         15. Use of Acetylsalicylic Acid (ASA) or NSAIDs (or any product containing ASA or NSAIDs)
             in the previous 7 days before day 1 of this study

         16. Use of MAO inhibitors within 30 days of day 1 of the study

         17. Positive urine drug screen or urine cotinine test at screening and prior to study drug
             administration

         18. Positive results to HIV, HBsAg or anti-HCV tests at screening

         19. Subjects who took an Investigational Product (in another clinical trial) in the
             previous 30 days (90 days for biologics) before day 1 of this study

         20. Donation of plasma within 7 days prior to dosing. Any donation/loss of blood or blood
             products within 3 months of the screening visit

         21. Prior exposure to MGCD265

        No subjects will be allowed to enroll in this study more than once (i.e. if the study is
        conducted with more than 1 group).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vince &amp; Associates Clinical Research, Inc.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2013</study_first_submitted>
  <study_first_submitted_qc>August 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2013</study_first_posted>
  <last_update_submitted>January 6, 2015</last_update_submitted>
  <last_update_submitted_qc>January 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>c-Met</keyword>
  <keyword>VEGFR</keyword>
  <keyword>Ron</keyword>
  <keyword>Cancer</keyword>
  <keyword>Tumor</keyword>
  <keyword>Safety</keyword>
  <keyword>Phase 1</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

